AGM/EGMMay 14, 2026, 07:32 AM
EDAP TMS 2026 AGM to Review Record 2025 HIFU Revenue, CE Mark
AI Summary
EDAP TMS SA reported a pivotal 2025, achieving record revenue in its HIFU business, driven by increased system placements and procedure volumes, particularly in the U.S. The company introduced Focal One i, an advanced HIFU platform, and secured a significant CE Mark in March 2025 for the treatment of posterior deep infiltrating endometriosis, expanding its indications beyond prostate cancer. The filing also details the agenda for the 2026 Annual General Meeting on June 26, 2026, including proposals for director renewals, financial statement approvals for 2025, and various capital increase delegations.
Key Highlights
- EDAP TMS achieved record revenue in its HIFU business for fiscal year 2025.
- Received CE Mark in March 2025 for Focal One Robotic HIFU to treat posterior deep infiltrating endometriosis.
- Introduced Focal One i, an advanced HIFU platform, expanding clinical capabilities.
- 2026 Annual General Meeting scheduled for June 26, 2026, to vote on 32 resolutions.
- Board recommends renewal of 6 directors and approval of 2025 financial statements.
- Shareholders to vote on various delegations for share capital increases.
- Board recommends "FOR" annual advisory vote on executive compensation.